China National Intellectual Property Administration

Purple Biotech Fortifies NT219 Patent Protection

Retrieved on: 
Thursday, November 2, 2023
Patient, Patent, SCCHN, Head, China National Intellectual Property Administration, Maintenance, Cetuximab, Neoplasm, Tumor microenvironment, Drug resistance, Escape Room, Neck, Pharmaceutical industry

REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted a new patent for maintaining a pharmaceutical composition of NT219 in its active form.

Key Points: 
  • The new patent granted in China (# CN 115466205 B) expands Purple Biotech’s patent protection for NT219 in China.
  • The drug was previously issued patent in China that relates to the combinations of NT219 with various anti-cancer agents.
  • “Expanding patent protection for NT219’s composition is strategic for Purple Biotech and we believe that the grant of this new patent marks another step forward in our global intellectual property strategy.
  • China is a large and important market opportunity for us, and strengthening our patent coverage improves our competitive positioning in this territory,” stated Purple Biotech CEO, Gil Efron.

De-MCU solution, Tinno is driving technological transformation in the tablet computer industry

Retrieved on: 
Monday, October 16, 2023
Patent, Pogo pin, MCU, Human, R, VIVO, China National Intellectual Property Administration, CMF, ODM, Tablet, Bluetooth, Software, Internet of things, Video game, Online shopping, Mobile phone, Android, China Telecom, Lenovo

SHENZHEN, China, Oct. 16, 2023 /PRNewswire/ -- Recently, Tinno Tech, (hereinafter referred to as "Tinno"), released its latest tablet device optimization solution.

Key Points: 
  • SHENZHEN, China, Oct. 16, 2023 /PRNewswire/ -- Recently, Tinno Tech, (hereinafter referred to as "Tinno"), released its latest tablet device optimization solution.
  • Currently, the connection between Android tablets and keyboards on the market is mainly achieved through pogo pin and Bluetooth.
  • To ensure connectivity, tablet manufacturers usually need to install an MCU (Micro Control Unit) inside the tablet, which is a common practice.
  • Brand manufactures want to know which keypad approach works best for them - and that is where Tinno can help.

LUMINELLE Announces China National Intellectual Property Administration’s Decision to Grant Issuance of Patent for LUMINELLE Bx (Biopsy) System, Expanding Global Footprint

Retrieved on: 
Thursday, October 5, 2023
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, Patent, Cancer, Food, China National Intellectual Property Administration, American Society of Clinical Oncology, CNIPA, Death, Mortality, Disease, Uterine cancer, Anesthesia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chinese patent medicine, Woman, Medical imaging, Biopsy

LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.

Key Points: 
  • LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.
  • 201880086268.8 titled “Biopsy Device and Method” for the LUMINELLE Bx System.
  • Issued on September 22, 2023, the new patent provides LUMINELLE with international intellectual property rights and allows the company to expand its technological footprint beyond the U.S. borders.
  • “The patent issuance from the CNIPA is a significant milestone for LUMINELLE as we continue to develop life-changing diagnostics for women everywhere,” said LUMINELLE CEO Allison London Brown.

The 4th Qingdao Multinationals Summit kicks off, highlights "Multinational Corporation and China"

Retrieved on: 
Wednesday, October 11, 2023
General Administration of Customs, United Nations, General Administration of Sport of China, China National Intellectual Property Administration, Multinational corporation, Development, Ministry of Trade and Industry, Commerce, Declaration of the United Nations Conference on the Human Environment, Ministry, Speech, Policy, Ministry of Commerce (Pakistan), United Nations Conference on Trade and Development, Conference, Pharmaceutical industry, Mining

QINGDAO, China, Oct. 11, 2023 /PRNewswire/ -- The opening ceremony of the fourth Qingdao Multinationals Summit was held today in Qingdao, Shandong province.

Key Points: 
  • QINGDAO, China, Oct. 11, 2023 /PRNewswire/ -- The opening ceremony of the fourth Qingdao Multinationals Summit was held today in Qingdao, Shandong province.
  • The summit is jointly organized by China's Ministry of Commerce and the Shandong Provincial Government.
  • The event brought together top management executives from 416 companies.
  • The summit also organized Multinational Corporation Symposium, Closed Door Meeting, China's Policy Interpretation and Project Promotion Conference on Attracting Foreign Investment and the Yellow River Basin Investment Cooperation Promotion Conference, Shandong Provincial Government Economic Consulting Consultant Conference, Shandong Provincial Industry Promotion Conference, Multinational Corporation Promotion Conference, etc.

The 4th Qingdao Multinationals Summit kicks off, highlights "Multinational Corporation and China"

Retrieved on: 
Wednesday, October 11, 2023
General Administration of Customs, Multimedia, United Nations, General Administration of Sport of China, China National Intellectual Property Administration, Multinational corporation, Development, Ministry of Trade and Industry, Commerce, Declaration of the United Nations Conference on the Human Environment, Ministry, Speech, Policy, Ministry of Commerce (Pakistan), United Nations Conference on Trade and Development, Conference, Pharmaceutical industry, Mining

QINGDAO, China, Oct. 11, 2023 /PRNewswire/ -- The opening ceremony of the fourth Qingdao Multinationals Summit was held today in Qingdao, Shandong province.

Key Points: 
  • QINGDAO, China, Oct. 11, 2023 /PRNewswire/ -- The opening ceremony of the fourth Qingdao Multinationals Summit was held today in Qingdao, Shandong province.
  • The summit is jointly organized by China's Ministry of Commerce and the Shandong Provincial Government.
  • The event brought together top management executives from 416 companies.
  • The summit also organized Multinational Corporation Symposium, Closed Door Meeting, China's Policy Interpretation and Project Promotion Conference on Attracting Foreign Investment and the Yellow River Basin Investment Cooperation Promotion Conference, Shandong Provincial Government Economic Consulting Consultant Conference, Shandong Provincial Industry Promotion Conference, Multinational Corporation Promotion Conference, etc.

Jointechlabs Enters China Regenerative Medicine Market with Joint Venture and Patent Grant

Retrieved on: 
Monday, October 2, 2023
China National Intellectual Property Administration, Patent, Arthralgia, Regenerative medicine, Hospital, Patient, Adipose tissue, Wound healing, Pharmaceutical industry, Dentistry

BRANDON, Fla., Oct. 2, 2023 /PRNewswire/ -- Jointechlabs, Inc., a Regenerative Medicine Solutions company announced that it has been granted a core patent by the China National Intellectual Property Administration covering adipose tissue processing and has entered into a joint venture with Bangyi Medical Technology Co., Ltd. to develop the aesthetic, plastic surgery, and orthopedic-sports medicine market in China.

Key Points: 
  • BRANDON, Fla., Oct. 2, 2023 /PRNewswire/ -- Jointechlabs, Inc., a Regenerative Medicine Solutions company announced that it has been granted a core patent by the China National Intellectual Property Administration covering adipose tissue processing and has entered into a joint venture with Bangyi Medical Technology Co., Ltd. to develop the aesthetic, plastic surgery, and orthopedic-sports medicine market in China.
  • "Innovation and market depth are key to our success and strategy as a pioneer and leader of the regenerative medicine industry," said Dr. Nathan Katz, CEO of Jointechlabs.
  • Jointechlabs also announced Zann Medical Technology Co., Ltd., a joint venture agreement with Bangyi, a leading provider of medical technology solutions in China.
  • Simon Chen, Managing Director and co-founder added "We are excited to work with Jointechlabs and together address regenerative medicine needs throughout China."

Glory Star’s Customer Mining Method and System Awarded China National Invention Patent

Retrieved on: 
Tuesday, September 12, 2023
China National Intellectual Property Administration, Data collection, Research, Blaze of Glory (Star Trek: Deep Space Nine), Data analysis, Acquisition, Patent, Mining, AI, CHEERS

The patent, granted to Glory Star's subsidiary CHEERS, is titled "Customer Mining Method and System Based on Customer Behavioral Characteristics," which propels the Company to the forefront of technological innovation in the field of customer acquisition.

Key Points: 
  • The patent, granted to Glory Star's subsidiary CHEERS, is titled "Customer Mining Method and System Based on Customer Behavioral Characteristics," which propels the Company to the forefront of technological innovation in the field of customer acquisition.
  • This patent marks a significant milestone, underscoring Glory Star's unwavering commitment to research and development excellence.
  • It encompasses a comprehensive range of cutting-edge features, including data collection, data preprocessing and analysis, customer clustering and mining, and result visualization.
  • "We are thrilled to have achieved this national invention patent for our revolutionary Customer Mining Method and System," Mr. Bing Zhang, Chairman and CEO of the Company, commented.

Chuncheng Heating Maintains High-Quality Development in 1H2023, Net profit Increases 95.9% year-on-year to RMB125 Million

Retrieved on: 
Tuesday, September 5, 2023
China National Intellectual Property Administration, Maintenance, Police Technology Department, Stock exchange, Intelligence, Research, Motherboard, Engineering, Economic development, Publicity Department of the Chinese Communist Party, Heat, AI, Renewable energy

Gross profit increased significantly by 77.2% to RMB226 million, primarily due to decrease in heat procurement costs, coal procurement, labor workers as well as utilities costs, etc.

Key Points: 
  • Gross profit increased significantly by 77.2% to RMB226 million, primarily due to decrease in heat procurement costs, coal procurement, labor workers as well as utilities costs, etc.
  • Net profit margin was 13.9% with earnings per share at RMB0.27.
  • It continued to improve its management system for heat supply production and enhanced the level of applying intelligence in heat supply business.
  • During the Period, the Group's revenue generated from heat supply business was RMB879 million, up by 2.1% year-on-year.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023
GMP, China National Intellectual Property Administration, Patent, Antigen, CNIPA, Partnership, IPSC, NKT, STAR, National University Hospital, Clinical trial, Cell, Immunotherapy, CN, NUH, Agency for Science, Technology and Research, Hematological Cancer Research Investment and Education Act, Biological patents in the United States, Risk, A*STAR, Cytomics, Blood, Agency, Cancer, Same, Outline of health sciences, Health Sciences Authority, T, HSA, NKG2D, Pharmaceutical industry, Vaccine, Science, Research

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

Arecor: Business Update

Retrieved on: 
Thursday, July 20, 2023
China National Intellectual Property Administration, Insulin, IPO, Partnership, American Diabetes Association, Emphysema, AIM, Diabetes, AREC, European Patent Office, Absorption, IP, AATD, Gold, Acquisition, Patient, Patent, European Patent Convention, Senior management, Growth, ADA, Inhalable insulin, RTU, US FDA, Type 2 diabetes, Fine chemical, Pharmaceutical industry

Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today provides a business update and announces that its interim results for the six months ended 30 June 2023 will be issued in mid-September.

Key Points: 
  • Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today provides a business update and announces that its interim results for the six months ended 30 June 2023 will be issued in mid-September.
  • Arecor is pleased to report strong progress across the business in the first half of 2023, with advances across its in-house and partnered programmes and continued success in the roll-out of Ogluo® in key territories.
  • Arecor looks forward to providing a full update on performance and outlook at the time of its interim results.
  • Later this year we expect key data for AT278 and anticipate further value inflection points within our licensed product portfolio.